Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis

医学 视神经脊髓炎 美罗华 荟萃分析 髓鞘少突胶质细胞糖蛋白 多发性硬化 内科学 光谱紊乱 视神经炎 扩大残疾状况量表 子群分析 相对风险 儿科 免疫学 抗体 置信区间 精神科 实验性自身免疫性脑脊髓炎
作者
Gregorio Spagni,Bo Sun,Gabriele Monte,Elia Sechi,Raffaele Iorio,Amelia Evoli,Valentina Damato
出处
期刊:Journal of Neurology, Neurosurgery, and Psychiatry [BMJ]
卷期号:94 (1): 62-69 被引量:39
标识
DOI:10.1136/jnnp-2022-330086
摘要

BACKGROUND: Rituximab (RTX) efficacy in patients with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disorders (MOGADs) is still poorly understood, though it appears to be lower than in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders (AQP4-IgG+NMOSDs). The aim of this systematic review and meta-analysis is to assess the efficacy and safety profile of RTX in patients with MOGAD and to compare RTX efficacy between MOGAD and AQP4-IgG+NMOSD. METHODS: We searched original English-language articles published between 2012 and 2021 in MEDLINE, Cochrane, Central Register of Controlled Trials and clinicaltrials.gov, reporting data on RTX efficacy in patients with MOGAD. The main outcome measures were annualised relapse rate (ARR) and Expanded Disability Status Scale (EDSS) score mean differences (MDs) after RTX. The meta-analysis was performed with a random effects model. Covariates associated with the outcome measures were analysed with a linear meta-regression. RESULTS: The systematic review included 315 patients (138 women, mean onset age 26.8 years) from 32 studies. Nineteen studies (282 patients) were included in the meta-analysis. After RTX, a significant decrease of ARR was found (MD: -0.92, 95% CI -1.24 to -0.60, p<0.001), markedly different from the AQP4-IgG+NMOSD (MD: -1.73 vs MOGAD -0.92, subgroup difference testing: Q=9.09, p=0.002). However, when controlling for the mean ARR pre-RTX, this difference was not significant. After RTX, the EDSS score decreased significantly (MD: -0.84, 95% CI -1.41 to -0.26, p=0.004). The frequency of RTX-related adverse events was 18.8% (36/192) and overall RTX-related mortality 0.5% (1/192). CONCLUSIONS: RTX showed effective in MOGAD, although to a lesser extent than in AQP4-IgG+NMOSD, while the safety profile warrants some caution in its prescription. Randomised-controlled trials are needed to confirm these findings and provide robust evidence to improve treatment strategies in patients with MOGAD. PROSPERO REGISTRATION NUMBER: CRD42020175439.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
骁龙完成签到 ,获得积分10
1秒前
shuaiwen25完成签到,获得积分10
2秒前
3秒前
3秒前
4秒前
4秒前
4秒前
4秒前
4秒前
xiw完成签到,获得积分10
6秒前
突然停电了完成签到,获得积分10
7秒前
8秒前
M83发布了新的文献求助10
8秒前
腾虎跃猿完成签到 ,获得积分10
8秒前
FFF完成签到,获得积分10
9秒前
9秒前
9秒前
阳光笑颜完成签到,获得积分10
12秒前
小王完成签到,获得积分10
13秒前
Taso17发布了新的文献求助10
13秒前
在水一方的应助被科研通管家采纳,获得20
16秒前
lyj完成签到,获得积分10
16秒前
LHH的应助被科研通管家采纳,获得10
16秒前
zxy的应助被科研通管家采纳,获得10
16秒前
无极微光的应助被科研通管家采纳,获得20
16秒前
Hello的应助被科研通管家采纳,获得10
16秒前
七月流火的应助被科研通管家采纳,获得10
17秒前
LHH的应助被科研通管家采纳,获得10
17秒前
深情安青的应助被科研通管家采纳,获得10
17秒前
just完成签到,获得积分10
21秒前
徐XU完成签到 ,获得积分10
21秒前
李笑蓉完成签到 ,获得积分10
22秒前
面包边完成签到,获得积分10
24秒前
执着鱼完成签到,获得积分10
24秒前
乘风完成签到,获得积分10
25秒前
moxin完成签到,获得积分10
27秒前
亓雅丽完成签到 ,获得积分10
28秒前
优美奇异果完成签到 ,获得积分10
29秒前
2025210129完成签到 ,获得积分10
30秒前
复杂初夏完成签到 ,获得积分10
31秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185571
求助须知:如何正确求助?哪些是违规求助? 9574290
关于积分的说明 21834928
捐赠科研通 7783274
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558973
邀请新用户注册赠送积分活动 2481370